دورية أكاديمية
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
| العنوان: | Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting. |
|---|---|
| المؤلفون: | Dawood S; Department of Medical Oncology, Mediclinic City Hospital - North Wing, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health Care City, Dubai, United Arab Emirates. shaheenah@post.harvard.edu., Konstantinova M; Department of Antitumor Drug Therapy, F. VladimirskIy Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia., Perazzo F; Department of Oncology, Centro de Educación Médicae Investigaciones Clínicas (CEMIC), Ciudad De Buenos Aires, Argentina., Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea., Villarreal-Garza C; Centro de Cancer de Mama, Hospital Zambrano Hellion, Tecnologico de Monterrey, Mexico; Depto. de Investigacion, Instituto Nacional de Cancerologia, Tlalpan, Ciudad de México., Franco SX; Department of Oncology, Clínica del Country, Bogotá, Colombia, Colombia., Simon SD; Centro Paulista de Oncologia (CPO), Faria Lima, 4300 - Vila Olímpia, São Paulo, Brazil., El-Nahas T; Kasr Al Ainy Hospital, Cairo university, Giza, Egypt. |
| المصدر: | Chinese clinical oncology [Chin Clin Oncol] 2020 Oct; Vol. 9 (5), pp. 61. Date of Electronic Publication: 2020 Aug 17. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: AME Publishing Company Country of Publication: China NLM ID: 101608375 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2304-3873 (Electronic) Linking ISSN: 23043865 NLM ISO Abbreviation: Chin Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hong Kong : AME Publishing Company |
| مواضيع طبية MeSH: | Immunotherapy/*methods , Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use , Triple Negative Breast Neoplasms/*drug therapy, Adult ; Female ; Group Processes ; Humans ; Neoplasm Metastasis ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology |
| مستخلص: | The therapeutic landscape of human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents such as poly-ADP ribose polymerase inhibitors (PARPi), novel chemotherapeutic agents, immunotherapy, and endocrine therapies. In this scenario, optimizing the appropriate treatment sequence is a daunting task for clinicians. To develop evidence-based answers to key clinical questions on treatment selection and appropriate treatment sequence for the management of patients with HER2- mBC in the era of PARPi, a breast cancer expert group meeting was convened. The expert panel comprised of eight key opinion leaders from Argentina, Brazil, Colombia, Egypt, Mexico, Moscow, South Korea, and the United Arab Emirates, who convened and reviewed the literature, discussed the clinical practices across the participating regions, and formulated answers to key clinical questions for optimizing the management of HER2- mBC. In this review, evidence-based answers have been provided pertaining to (I) the specific mBC population to be considered for BRCA testing, optimal time point of BRCA testing, and genetic counselling in mBC patients; (II) the role of PARPi versus platinum therapy in HER2- mBC patients in the metastatic setting; (III) sequencing treatment in metastatic triple-negative breast cancer (TNBC) and hormone receptor-positive HER2- mBC patients, and defining the place of PARPi in the sequencing algorithms; and (IV) the need for a breast cancer registry for patients with HER2- mBC. This expert review will serve as a comprehensive guide to clinicians for optimizing BRCA testing and managing patients with BRCA mutation (BRCAm) and HER2- mBC. The data collected from the proposed HER2- mBC registry will help understand the treatment practices, identify unmet needs, and develop strategic policies regionally to help improve access to optimized care of HER2- mBC. |
| فهرسة مساهمة: | Keywords: BRCA mutations; Human epidermal growth factor receptor; breast cancer; immunotherapy; poly-ADP ribose polymerase inhibitors (PARPi) |
| المشرفين على المادة: | 0 (Poly(ADP-ribose) Polymerase Inhibitors) |
| تواريخ الأحداث: | Date Created: 20200822 Date Completed: 20210608 Latest Revision: 20210608 |
| رمز التحديث: | 20231215 |
| DOI: | 10.21037/cco-20-138 |
| PMID: | 32819114 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!